Activities
HER2+ Metastatic Breast Cancer: What Targeted Therapy Means for Managed Care
0290-0000-20-239-L01-P
This virtual symposium will examine the role and use of biomarker testing for HER2+ breast cancer and its impact on therapy decisions.
11-09-2020
1.50
Gastrointestinal Cancers: Managed Care Strategies to Improve Resource Utilization With Immune Checkpoint Inhibitors
0290-0000-20-279-L01-P
This virtual symposium will explain the influence biomarker testing assays have on the overall cost of drug therapy for patients with gastrointestinal (GI) cancer who are receiving treatment with an immune checkpoint inhibitor.
11-09-2020
1.50
Advancements in Metastatic Triple-Negative Breast Cancer: Treatment Discussions and Managed Care Considerations
0290-0000-20-252-L01-P
This virtual symposium will explain the pathophysiology, prognosis, and challenges of treating metastatic triple-negative breast cancer.
11-10-2020
1.50
Hepatocellular Carcinoma: The Evolving Treatment Landscape and Cost Utilization Strategies
0290-0000-20-238-L01-P
This virtual symposium will determine ways in which care coordination in the treatment of hepatocellular carcinoma (HCC) can impact overall utilization resources.
11-10-2020
1.50